Drug Name:
SKELID Rx
Generic Name and Formulations:
Tiludronate disodium 240mg (equivalent to tiludronate acid 200mg); tabs.
Company:
Sanofi U.S.
Therapeutic Use:
Indications for SKELID:
Treatment of Paget's disease of bone (osteitis deformans) in patients (1) who have a level of serum alkaline phosphatase at least twice the upper limit of normal, or (2) who are symptomatic, or (3) who are at risk for future complications of their disease.
Adult:
Take with 6–8oz of plain water on an empty stomach. 400mg once daily for 3 months. Do not lie down for at least 30 minutes.
Children:
Not recommended.
Contraindications:
Inability to stand or sit upright for at least 30 minutes.
Warnings/Precautions:
Active upper GI disease; discontinue and reevaluate if signs/symptoms of esophageal reaction occur. Severe renal impairment (CrCl <30mL/min): not recommended. Ensure adequate Vit. D and calcium intake. Pregnancy (Cat.C). Nursing mothers.
Pharmacological Class:
Bisphosphonate.
Interactions:
Calcium, aluminum, magnesium, other divalent cations reduce absorption (separate dosing by at least 2hrs). Caution with aspirin, NSAIDs, other GI irritants. Potentiated by indomethacin, separate dosing by 2hrs.
Adverse Reactions:
GI upset; musculoskeletal pain (may be severe), esophagitis; esophageal ulcer, stricture, or erosion, jaw osteonecrosis; rarely: gastric or duodenal ulcer.
How Supplied:
Tabs (200mg)—56
Clinical Pain Advisor Articles
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Predicting Pain Chronicization After Spine Surgery
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- Medicaid Expansion Under the ACA Increased Access to Opioid Use Disorder Treatments
- DEA Proposal Will Significantly Cut Opioid Manufacturing in 2019
- Survey Says: Perspectives From Women in Health Care
- Butalbital/APAP Capsules Launched for Complex Tension Headache
- Concomitant Use of Pregabalin and Opioids May Increase Risk for Opioid-Related Death
